SCHEMBL18397935

SCHEMBL18397935

O=C(O)NCc1cc(=O)c2ccc(Nc3cnn(-c4ccccc4)c3)cc2o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.40
▸ MAPT P10636 4/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ MAPK8 P45983 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ POLB P06746 2/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HTT P42858 3/20 0.37
▸ ATM Q13315 1/20 0.37
▸ EGFR P00533 1/20 0.36
▸ FGFR1 P11362 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ NPSR1 Q6W5P4 3/20 0.36
▸ STAT6 P42226 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18397850 0.86 LOXL2 (0.44) ALDH1A1MAPTKDM4EHPGDCYP1A2
Hydrochloric Acid SCHEMBL18397895 0.85 LOXL2 (0.46) ALDH1A1MAPTKDM4EHPGDCYP1A2
SCHEMBL18397944 0.76 EGLN1 (0.42) MAPK8POLB
SCHEMBL18397884 0.73 POLB (0.42) KDM4EMAPK8POLBLMNAHTT
SCHEMBL20423833 0.72 CA12 (0.58) CYP19A1
SCHEMBL18397753 0.70 LOXL2 (0.61) ALDH1A1KDM4EHPGDCYP1A2CYP3A4
SCHEMBL18397846 0.69 POLB (0.43) MAPTPOLBL3MBTL1LMNARAB9A
SCHEMBL18397739 0.67 LOXL2 (0.62) POLBLMNA
SCHEMBL19211232 0.66 AXL (0.37) EGFRFGFR1KDRJAK3
SCHEMBL18397917 0.66 LOXL2 (0.44) MAPK8POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180215727-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2018-08-02 — — US disclosed
EP-3325462-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF Pharmakea, Inc. (US) 2018-05-30 — — EP disclosed
WO-2017015221-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2017-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180215727-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX ALDH1A1 982/4885MAPT 3741/4885KDM4E 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback